Trial Profile
CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Cisplatin; Docetaxel; Pemetrexed
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms CHIO3 Trial
- 06 Feb 2024 Planned End Date changed from 1 Sep 2024 to 1 Jun 2026.
- 06 Feb 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Dec 2025.
- 06 Feb 2024 Status changed from recruiting to active, no longer recruiting.